Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)

Date: November 16, 2020
Issue #: 
1611Summary: 
The FDA has approved two new drugs for treatment
of previously-treated unresectable or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki
(Enhertu– Daiichi-Sankyo/AstraZeneca), an IV
HER2-directed monoclonal antibody linked to the
topoisomerase I inhibitor DXd, and tucatinib (Tukysa– Seagen), an oral tyrosine kinase inhibitor.

Source: The Medical Letter - November 6, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research